Emmune, Inc
Publicly observedJuno Beach, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Juno Beach | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Emmune, Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | N65ZDYUGWAH8 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Sept 2026Publicly observed
NIH SBIR/STTR award: Non-viral gene therapy to treat and prevent atherosclerosis
USD 299,664.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2026Publicly observed
NIH SBIR/STTR award: PK, tolerability, and toxicology studies for eCD4-Ig as a long-acting recombinant protein therapeutic
USD 299,352.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant9 May 2025Publicly observed
NIH SBIR/STTR award: IND-enabling studies for eCD4-Ig as a long-acting recombinant protein therapeutic
USD 300,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant17 Aug 2023Publicly observed
NIH SBIR/STTR award: SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jan 2023Publicly observed
NIH SBIR/STTR award: Process development for manufacturing eCD4-Ig
USD 999,997.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.